The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - AstraZeneca
 
Employment - AstraZeneca
Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
 
Weimin Li
No Relationships to Disclose
 
Athena Matakidou
Employment - AstraZeneca
 
Zara Ghazoui
No Relationships to Disclose
 
Han Si
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Sophie Wildsmith
Employment - AstraZeneca
 
Nassim Morsli
Employment - AstraZeneca
 
Helen Mann
Employment - AstraZeneca
 
Magdalena Wrona
Employment - AstraZeneca
 
Melissa de Los Reyes
Employment - AstraZeneca
 
Rajiv Raja
Employment - AstraZeneca
 
Craig Barker
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Jessica Whiteley
Employment - AstraZeneca
 
Qu Zhang
Employment - AstraZeneca
 
Jerome Fayette
Honoraria - AstraZeneca; Biogen; Bristol-Myers Squibb; Innate Pharma; Merck Serono; Merck Sharp & Dohme
Consulting or Advisory Role - AstraZeneca; BIOGEN; Bristol-Myers Squibb; Innate Pharma; Merck Serono; Merck Sharp & Dohme
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme
 
Dan Paul Zandberg
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Macrogenics (Inst); Merck (Inst)
 
Ricard Mesia
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck KGaA; MSD; Nanobiotix; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; MSD
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Roche
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; GlaxoSmithKline; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)